Kalaris Therapeutics, Inc.
KLRS
$3.41
-$0.06-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.52M | -10.86M | -10.00M | -11.89M | -11.35M |
| Total Depreciation and Amortization | 10.00K | 10.00K | 10.00K | 3.00K | -- |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Other Non-Cash Items | 573.00K | 402.00K | 58.00K | 567.00K | 591.00K |
| Change in Net Operating Assets | -114.00K | -1.14M | 2.87M | -9.00K | -1.78M |
| Cash from Operations | -11.05M | -11.58M | -7.06M | -11.33M | -12.54M |
| Capital Expenditure | -- | -- | -17.00K | -183.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.17M | -50.35M | 15.00M | -34.52M | -- |
| Cash from Investing | 20.17M | -50.35M | 14.98M | -34.71M | -- |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.00K | 74.00K | 42.00M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -387.00K | -1.77M | 5.74M | 0.00 | 0.00 |
| Cash from Financing | -377.00K | -1.70M | 47.74M | 0.00 | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.75M | -63.63M | 55.67M | -46.04M | -12.54M |